The effect of omega-3 and zinc in the treatment of diabetes

The effect of supplemental omega-3 and zinc supplementation on inflammation, lipid profiles and antioxidant capacity in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170214032571N2

Enrollment

Registered

2018-01-13

Start date

2016-09-30

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Diabetes mellitus

Interventions

Intervention 1: Group A = Intervention group with omega-3 doses of 1000 mg with lunch. Intervention 2: Group C = Omega 3 group with zinc. Intervention 3: Group A = Intervention group with zinc dose

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: tendency to Cooperation Type 2 diabetic patients ; taking metformin or glibenclamide glucose or similar drugs by patients Age range 18 to 65 years use of lipid lowering statin drugs and a blood pressure lowering drugs

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the study Insulin injection Do not consume 80% of supplements per course People with pancreatic cancer and patients receiving steroidal anti-inflammatory drugs (due to secondary hyperglycemia) severe physical activity Use of omega-3 and zinc supplementation in the last three months developing any underlying coronary artery disease and cancer taking antidepressants (because of interactions with zinc supplementation)

Design outcomes

Primary

Measure	Time frame
Total cholesterol. Timepoint: Before intervention and two months after intervention. Method of measurement: Enzymatic method, mg / dl.;TAC. Timepoint: Before intervention and two months after intervention. Method of measurement: Colorimetric.;Hs-crp. Timepoint: Before intervention and two months after intervention. Method of measurement: Eliza-mg/dl.;HDL. Timepoint: Before intervention and two months after intervention. Method of measurement: Enzymatic method, mg / dl.;Tri glyceride ??. Timepoint: Before intervention and two months after intervention. Method of measurement: Enzymatic method, mg / dl.;LDL. Timepoint: Before intervention and two months after intervention. Method of measurement: Enzymatic method, mg / dl.	—

Measure

Time frame

Total cholesterol. Timepoint: Before intervention and two months after intervention. Method of measurement: Enzymatic method, mg / dl.;TAC. Timepoint: Before intervention and two months after intervention. Method of measurement: Colorimetric.;Hs-crp. Timepoint: Before intervention and two months after intervention. Method of measurement: Eliza-mg/dl.;HDL. Timepoint: Before intervention and two months after intervention. Method of measurement: Enzymatic method, mg / dl.;Tri glyceride ??. Timepoint: Before intervention and two months after intervention. Method of measurement: Enzymatic method, mg / dl.;LDL. Timepoint: Before intervention and two months after intervention. Method of measurement: Enzymatic method, mg / dl.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Monafi

Urmia University of Medical Sciences

MAJIDMANAFI@YAHOO.COM+98 44433659218

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026